26
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protocolo POG 9061 en la recaída aislada a sistema nervioso central en pacientes con diagnóstico de leucemia linfoide aguda. Resultados de una serie de casos en el Hospital Universitario de Santander Translated title: POG 9061 protocol to treat isolated central nervous system recurrence in patients with acute lymphoid leukemia at Hospital Universitario de Santander

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introducción: La leucemia linfoide aguda (LLA) es la neoplasia más común en niños; el 5-10 % presentan recaídas a sistema nervioso central (SNC), un factor de mal pronóstico. Objetivo: Describir los resultados obtenidos en una unidad de oncología pediátrica con el protocolo POG 9061 modificado, en pacientes con LLA y recaída aislada a SNC. Metodología: Cohorte de los pacientes atendidos en el Hospital Universitario de Santander (HUS). Se estimó la sobrevida libre de evento (SLE) y la sobrevida total (ST), así como las alteraciones resultantes del protocolo. Se incluyeron 15 pacientes atendidos entre enero/93 y marzo/07; el último diagnóstico de recaída al SNC se hizo en noviembre/04. Resultados: El 66,6 % de las recaídas se dieron antes de 18 meses luego de remitir la LLA. Dos pacientes abandonaron el protocolo, uno de los cuales falleció; dos o más fallecieron luego de terminar el protocolo. La ST a cinco años fue de 85,6 % (IC95 % 53,3-96,2), mientras que la SLE de 84,9 % (IC95 % 51,2-96,0 %). La complicación más frecuente fue mielosupresión; no hubo alteraciones de la función renal y solo una ligera elevación de las pruebas de función hepática. Las causas de hospitalización fueron principalmente infecciones. El coeficiente intelectual de los pacientes posterior a la aplicación del protocolo indicaba deficiencia leve en el 45,4 % de ellos. Conclusiones: La sobrevida, el tipo y la frecuencia de complicaciones, son similares a las encontradas a nivel mundial, lo que es relevante dada la alta proporción de pacientes con recaída precoz luego de remisión de la LLA. Salud UIS 2010; 42: 7-17

          Translated abstract

          Introduction: Acute lymphoblastic leukemia (ALL) is the most frequent neoplasm in children. Relapses to central nervous system (CNS) Appears in 5-10 % of the ALL patients and is a bad prognostic factor. Objective: To describe the results obtained with modified POG 9061 protocol in a pediatric oncology unit. Methodology: Survival analysis was made and main complications caused by protocol were analyzed in a retrospective cohort with all of patients attended for ALL with isolated relapse to CNS. Results: Fifteen patients attended from 1993 to 2007 were included; 66.6 % CNS relapses were early to 18 mounts following ALL remission. Two patients left protocol, with one death; there were another two deaths among other patients. Five year global survival rate was 85.6 % (95 %CI 53.3-96.2 %), and event-free survival rate was 84.9 % (95 %CI 51.2-96.0 %). The most frequent complication was mielosupression; renal function alteration was not observed, with a light elevation of hepatic function tests. Infection was the main hospitalization cause. Conclusions: Survival rates and complications (type and frequency) are similar to the other studies. This finding is relevant because half of the patients had early CNS relapse after ALL remission. Salud UIS 2010; 42: 7-17.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: not found
          • Article: not found

          Treatment of acute lymphoblastic leukemia.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.

              Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin-Frankfurt-Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). Patients were treated in up to 82 centers in Germany, Austria and Switzerland. Probability of 10-year event-free survival (EFS) (survival) improved from 65% (77%) in study ALL-BFM 81 to 78% (85%) in ALL-BFM 95. In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment. The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.
                Bookmark

                Author and article information

                Journal
                suis
                Revista de la Universidad Industrial de Santander. Salud
                Rev. Univ. Ind. Santander. Salud
                Universidad Industrial de Santander (Bucaramanga, Santander, Colombia )
                0121-0807
                2145-8464
                April 2010
                : 42
                : 1
                : 7-17
                Affiliations
                [01] Bucaramanga orgnameUniversidad Industrial de Santander orgdiv1Facultad de Salud orgdiv2Escuela de Medicina Colombia
                Article
                S0121-08072010000100002 S0121-0807(10)04200102
                878108b0-cd1d-460b-bb8d-43a2a9d56ef5

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 01 March 2010
                : 30 March 2010
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 34, Pages: 11
                Product

                SciELO Colombia

                Categories
                Artículos Originales

                daunorrubicine,vincristine,local neoplasm recurrence,Lymphoid leukemia,daunorrubicina,vincristina,recurrencia local de neoplasia,terapia,Leucemia linfoide

                Comments

                Comment on this article